PO

Polaris AI Pharma Corp.

A global supplier of generic APIs using AI to accelerate drug development.

041910 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 발안공단로 25, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Polaris AI Pharma Corp., formerly Estechpharma, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs). The company specializes in the production of generic APIs, with a portfolio of approximately 40 products for various therapeutic areas, including anti-thrombotic, anti-inflammatory, and treatments for gastric ulcers and asthma. A key strategic focus is the integration of artificial intelligence into its research and development pipeline to predict the success of drug candidates and optimize clinical trial designs, thereby accelerating the development process. Polaris AI Pharma serves both domestic and international pharmaceutical markets and engages in joint research for innovative drug delivery systems.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 884.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-12 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 19.8 KB
2025-08-12 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 15.7 KB
2025-08-07 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 20.0 KB
2025-08-01 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.5 KB
2025-07-07 00:00
M&A Activity
주요사항보고서(유형자산양수결정)
Korean 15.9 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 907.9 KB
2025-03-20 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.5 KB
2025-03-12 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 540.9 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 19.4 KB
2025-03-05 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.9 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 118.6 KB

Automate Your Workflow. Get a real-time feed of all Polaris AI Pharma Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Polaris AI Pharma Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.